Explore this article's sources with AI
Follow PeptideMethods on Google
Resistance Exercise With Tirzepatide
A 40-week randomized trial found that supervised resistance exercise reduced lean soft tissue loss and improved strength during tirzepatide treatment.
Why we wrote this. This completed trial directly tests whether supervised resistance exercise changes lean tissue and strength during tirzepatide treatment, a question often discussed without randomized evidence.
In this article (5 sections)
A completed randomized trial found that supervised resistance exercise reduced, but did not prevent, loss of lean soft tissue mass during 40 weeks of tirzepatide treatment. All 120 participants received tirzepatide. Randomization assigned 59 people to three supervised resistance sessions each week and 61 to continue their usual activities. The comparison therefore tested the added exercise program, not tirzepatide against placebo[1].
Body weight fell by a similar amount in both groups: 22.28 kg with exercise and 22.61 kg with usual activity. Total fat mass also fell similarly. The result is not that exercise produced more weight loss. It is that participants assigned to the structured program retained more lean soft tissue and gained strength while losing about the same amount of weight[1].
How the T-REx trial was run
The single-center T-REx trial enrolled community-dwelling men and postmenopausal women aged 50 to 70. Participants had obesity, or overweight with at least one weight-related condition, and reported less than 60 minutes of moderate or harder exercise per week before enrollment. The trial excluded people with diabetes, cardiovascular disease, prior incretin therapy and several other conditions. Half of the cohort was female, and the mean age was 57.7 years[1][2].
Treatment was open label. Tirzepatide started at 2.5 mg weekly and could be increased every four weeks toward 15 mg, with slower escalation or a lower tolerated dose allowed. The exercise group attended three one-hour, center-based sessions each week. Qualified exercise physiologists supervised a progressive program that moved from technique work toward strength and hypertrophy training. Mean attendance was 91%[1]. This was a closely supported research program, not simply advice to exercise.
The two co-primary outcomes were change in total fat mass and total lean soft tissue mass measured by DXA. DXA separates fat, lean soft tissue and bone mineral content, but lean soft tissue is not identical to skeletal muscle. Appendicular lean soft tissue and one-repetition maximum strength tests for bench press, lat pulldown and knee extension supplied related evidence[1].
Lean tissue loss was smaller, not eliminated
At week 40, total lean soft tissue had decreased by 4.67 kg in the usual-activity group and 3.57 kg in the resistance exercise group. The adjusted between-group difference was 1.09 kg, and its confidence interval excluded no difference. Appendicular lean soft tissue also declined in both groups, with an estimated 0.63 kg advantage for exercise. These findings show attenuation rather than complete preservation[1].
The fat-mass co-primary outcome moved differently. Fat mass fell by 17.19 kg with usual activity and 17.98 kg with exercise. The between-group estimate was minus 0.77 kg, with a 97.5% confidence interval from minus 2.14 to 0.60 kg. That interval crossed zero, so the trial did not show an added fat-loss effect from the resistance program[1].
The lean-tissue trajectory also matters. Most of the decline in total lean soft tissue occurred by week 24 and then appeared to plateau. Appendicular lean soft tissue continued to decline through week 40. Follow-up ended with treatment, so the trial does not show whether either pattern persisted after tirzepatide or supervised training stopped[1].
Strength moved in opposite directions
Bench press, lat pulldown and knee extension strength decreased in the usual-activity group by 4.09 kg, 4.42 kg and 4.42 kg. In the exercise group, the same measures increased by 4.68 kg, 8.58 kg and 5.88 kg. The resulting differences between groups were large and consistent across the three tests[1]. Strength testing was not blinded, however, because some exercise physiologists who supervised training also conducted assessments.
Blood pressure, glucose measures, total cholesterol and triglycerides improved over time in both groups, without evidence that resistance exercise added to those changes. Because everyone received tirzepatide and there was no non-drug placebo group, those before-and-after changes cannot by themselves separate the medicine's effect from other influences within this trial[1].
Safety and completion
One hundred eleven participants, or 93%, completed the study. Six withdrew because of adverse events, two after a breast cancer diagnosis and one for personal reasons. Nausea was reported by about half of participants. Vomiting, constipation, diarrhea and indigestion were each reported by about one-third, with similar frequencies between groups. Six serious adverse events occurred and investigators assessed all as unrelated to tirzepatide or the exercise intervention[1]. A trial of this size and duration cannot rule out rare or delayed harms.
Eli Lilly supplied tirzepatide through an investigator-initiated trial program and reviewed the protocol and a manuscript draft, but the authors reported that the company provided no other funding and did not conduct the trial. Several authors disclosed speaker honoraria or advisory relationships involving Lilly and other companies[1].
What we do not yet know
The study population was initially sedentary and limited to men and postmenopausal women aged 50 to 70 without diabetes or cardiovascular disease. The findings may not extend to younger adults, premenopausal women, trained people or patients with those conditions. The feasibility of three supervised gym sessions each week also needs testing in routine care. High attendance in a single research center may be difficult to reproduce[1].
The trial measured DXA-derived lean soft tissue and regional strength, not falls, disability, quality of life or long-term clinical outcomes. It also provided no specific dietary intervention, although participants were told to maintain protein intake. Future work must test whether the retained tissue and strength translate into durable functional benefit and which exercise designs are practical outside a supervised program.
This completed trial gives stronger evidence than an announced protocol or an uncontrolled body-composition report. It supports discussing resistance training as part of care during prescribed tirzepatide, while stopping short of a universal exercise prescription. The broader tirzepatide evidence overview and the semaglutide evidence overview provide context for the medicines, but neither page replaces individual assessment of health, mobility and training experience.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Did resistance exercise prevent all lean tissue loss with tirzepatide?
No. Total lean soft tissue decreased in both groups. The loss was 3.57 kg with supervised resistance exercise and 4.67 kg with usual activity, an adjusted difference of 1.09 kg at week 40.
Did the exercise group lose more weight?
No clear difference emerged. Mean weight loss was 22.28 kg with resistance exercise and 22.61 kg with usual activity. Fat-mass loss was also similar between groups.
How often did participants do resistance exercise?
The intervention used three supervised, one-hour, center-based sessions each week for 40 weeks. Attendance averaged 91%, so the result reflects a structured program with unusually close support.
Does this trial define the right exercise plan for everyone using tirzepatide?
No. Participants were sedentary adults aged 50 to 70 without diabetes or cardiovascular disease. The study did not compare different training programs or test whether the supervised schedule is practical in routine care.
Sources
- [1]Green DJ et al. Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial. Nature Medicine. 2026. PMID 43003902.Tier 1 · primary↩
- [2]WHO International Clinical Trials Registry Platform. T-REx trial record ACTRN12623001236684.Tier 1 · primary↩
No revisions yet. First published .